Absolute monocyte count as a prognostic parameter in diffuse large B cell lymphoma
ABSTRACT Background Prognosis of patients with Diffuse Large B Cell Lymphoma (DLBCL) is highly variable, and despite the use of modern immunochemotherapy regimens, almost 50% of patients will eventually relapse. Standard risk models, like the International Prognostic Index or the Revised Internatio...
Guardado en:
Autores principales: | IRIGOÍN,VICTORIA, OLIVER,CAROLINA, LÓPEZ,STEFANÍA, LANDONI,ANA INÉS, GABÚS,RAÚL, DÍAZ,LILIÁN |
---|---|
Lenguaje: | English |
Publicado: |
Sociedad Médica de Santiago
2019
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201553 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment
por: Wei Wang, et al.
Publicado: (2021) -
Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma
por: Akiko Hashimoto, et al.
Publicado: (2021) -
The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matched Analysis
por: Shen Z, et al.
Publicado: (2021) -
Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature
por: Mengwei Ren, et al.
Publicado: (2021) -
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang F, et al.
Publicado: (2019)